Korean drugmakers eye generic Exforge development

Published: 2012-06-07 06:59:00

Updated: 2012-06-07 06:59:00

Korean pharmaceutical firms are gearing up to enter the ever-growing combination antihypertensive drugs market dominated by foreign drug companies – Novartis, Daiichi Sankyo and Boehringer Ingelhiem.

The patent of the market leader, Novartis’s Exforge, is set to expire in September 2012, allow...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK